Potentiation of humoral response to the BNT162b2 vaccine after the third dose in patients with solid cancer

Immunogenicity and safety after the third dose of BNT162b2 anti-SARS-CoV-2 vaccine in patients with solid tumors on active treatment: a prospective cohort study

“…In our cohort, the neutralizing activity was significantly higher in seroconverted patients, with a positive correlation between IgG levels and NT Abs titre. This correlation has also been reported in other papers: Di Noia and colleagues have found a strong correlation between the levels of anti-S IgG and the titre of NT Abs [23]. Also Levin et at have reported a strong correlation between IgG and NT Abs for the whole six months after the full course of vaccine (Spearman's rank correlation between 0.68 and 0.75), with a time-dependent regression relationship [14].…”

“…The patient who failed to successfully seroconvert at T1 was under daily corticosteroid treatment during the vaccination schedule for concomitant rheumatoid arthritis. This negative association between steroid treatment and IgG levels has been described in many papers [21][22][23].…”

Duration of humoral response to the third dose of BNT162b2 vaccine in patients with solid cancer: Is fourth dose urgently needed?

“…We had previously reported on the immunogenicity of the BNT162b2 mRNA COVID-19 vaccine (Tozinameran) in a large cohort of patients with cancer after the first and the second doses [ 1 ], and we subsequently showed the rapid decline of humoral response over the time until 6 months of follow-up [ 2 , 3 ]. We have also recently reported on the potentiation of humoral response after the third dose in this frail population [ 4 ], in line with other studies [ [5] , [6] , [7] , [8] , [9] ].…”

“…The proportion of patients with a positive serological status was 97.7% (211/216) similar to that observed (98.8%, 402/407) in the post-1 month analysis, previously reported [ 4 ]. The GMC at 4-months was 653.61 AU/ml, lower than the value previously assessed at 1-month after the booster (1054.5 AU/ml).…”

Humoral and cellular responses to mRNA-based COVID-19 booster vaccinations in patients with solid neoplasms under active treatment

“…titers affected by therapy intensity (targeted vs chemo), cellular response not affected (but lower than in healthy controls) Di Noia V, Ann Oncol. ( 38 ) BNT162b2 4 weeks yes no no 407 366 (90%) on active anticancer treatment (Therapy type, antibodies, chemo/antibody, IO, targeted, hormonal) 0 0 98.8% seropositive after booster, sign. increase of humoral response after booster; only use of steroids sign.…”